Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021

07/29/2021 | 08:01am EDT

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2021 financial results and provide a corporate update before market open on Thursday, August 5, 2021. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00am ET.

Conference Call and Webcast
To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 4291658. The live webcast can be accessed under “Events & Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce obtained IND clearance for and exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contacts:

Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com

Julie Seidel
Stern Investor Relations
+1-212-362-1200
Julie.Seidel@sternir.com


Primary Logo


ę GlobeNewswire 2021
All news about JOUNCE THERAPEUTICS, INC.
09/15JOUNCE THERAPEUTICS : Departures of Directors or Certain Officers; Election of Directors; ..
PU
09/15JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/15Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
GL
09/15Jounce Therapeutics, Inc. Announces Board Changes
CI
09/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/14JOUNCE THERAPEUTICS : Raymond James Upgrades Jounce Therapeutics to Outperform From Market..
MT
09/02Jounce Therapeutics to Present at Upcoming Investor Conferences in September
GL
08/05JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/05Jounce Therapeutics Reports Second Quarter 2021 Financial Results
GL
08/05JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
More news
Analyst Recommendations on JOUNCE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 46,1 M - -
Net income 2021 -68,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,90x
Yield 2021 -
Capitalization 420 M 420 M -
Capi. / Sales 2021 9,10x
Capi. / Sales 2022 22,6x
Nbr of Employees 128
Free-Float 81,7%
Chart JOUNCE THERAPEUTICS, INC.
Duration : Period :
Jounce Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOUNCE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 8,19 $
Average target price 14,50 $
Spread / Average Target 77,0%
EPS Revisions
Managers and Directors
Richard Murray President, Chief Executive Officer & Director
Kimberlee Cobleigh Drapkin Chief Financial Officer & Treasurer
Perry A. Karsen Chairman
Elizabeth G. Trehu Chief Medical Officer
Stephen Farrand Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
JOUNCE THERAPEUTICS, INC.17.00%420
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634